- Cite Score
Why subscribe and read
We would like to present to you the Forum of Clinical Oncology (FCO), the official scientific journal of the Hellenic Society of Medical Oncology.
In the Hellenic Society of Medical Oncology we want FCO to serve as a forum, for us all, to communicate clinical and research achievements in English; to share thoughts, opinions, facts, problems and solutions.
We envision the journal to be the means, by which our efforts in the fight against cancer will become known to a wider audience, thus establishing our presence in the global setting. FCO publishes original and translational research articles relevant to diagnosis and treatment of cancer, state-of-the-art reviews, case reports, research articles, statements of opinion and comments, all related to clinical practice and basic research. A large number of eminent Greek and Foreign colleagues who participate in the National and International Editorial Boards, with their continuum direction and support, guarantee the high quality of the work published in FCO. In every issue published there will be something new, enjoyable and exciting to be read.
We would like to welcome you to the Forum of Clinical Oncology (FCO), the official scientific journal of the Hellenic Society of Medical Oncology.
In the Hellenic Society of Medical Oncology we share the view that there are many issues we deal with in our everyday clinical and research practice that are common to our colleagues geographically closer to us, in the Balkans and the Mediterranean basin, but also to those in other parts of the world. That led us to dare "the great leap forward": to broaden the scope of our Greek scientific journal for oncology, published in Greek for the last 10 years, and develop Forum of Clinical Oncology a web based open access journal in English.
FCO will serve as a forum for us all to communicate clinical and research achievements. One of the innovations of the journal is its online management from submission of an article to its publication. Online is more efficient: submitting, reviewing, proofreading, filing and indexing. However, the most important benefit of all is easy universal access.
English has become the common language amongst scientists from around the globe. This is the reason why we chose English as the official language of the journal. Many Greek colleagues have already published work in English in distinguished journals or have studied or worked abroad. We believe that the language change will not be an impediment for our Greek colleagues to present their work in FCO, whereas on the other hand it will allow our colleagues from other countries to participate.
The Forum of Clinical Oncology publishes original and translational research articles relevant to diagnosis and treatment of cancer, state-of-the-art reviews, case reports, research articles, statements of opinion and comments, all related to clinical practice and basic research.
We share the view that there should be no barriers to knowledge and thus, we decided Forum of Clinical Oncology to be an open-access journal, i.e., any work submitted to the journal and accepted for publication shall be made immediately available to the scientific community and the general public, via the journal's website and printed version. Authors are requested to adjust accordingly the information regarding their work they wish to make public. It is the desire of the editorial team to make this journal an interactive educational tool to acquire knowledge and it is addressed to scientists working with oncology.
Please join us in our effort and submit your work to the FCO.
Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.
The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process.
Nikolaos Tsoukalas, MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Deputy Director, Oncology Department,
401 General Military Hospital, Consultant, Henry Dunant Hospital Center, Athens, Greece, HeSMO
Michael Liontos, Medical Oncologist, Associate Professor of Therapeutics-Oncology, National and Kapodistrian University of Athens, Dept of Clinical Therapeutics, Alexandra Hospital, Athens, Greece, HeSMO
Evangelos Karamitrousis, MD, PhD, MSc, BSc, Medical Oncology Consultant, University Medical Oncology Department, Papageorgiou General Hospital, Thessaloniki, Greece, HeSMO
Advisory Editorial Board
Rene Adam, Paul Brousse Hospital, France
Athanassios Argiris, University of Pittsburgh School of Medicine, United States
Vassileios Avramis, Children's Hospital Los Angeles, United States
Lodovico Balducci, Lee Moffitt Cancer Center and Research Institute, United States
George Peter Canellos, Harvard Medical School, United States
J.Y. Douillard, Medical Oncology Branch, Centre R. Gauducheau, France
George Demetri, Dana-Farber Cancer Institute, United States
Spyros Linardopoulos, Cancer Research UK Centre for Cancer Therapeutics, Chester Beatty Laboratories, United Kingdom
Terry Mamounas, Cancer Center, Aultman Health Foundation, United States
Anthony Maraveyas, Castle Hill Hospital, United Kingdom
Vassiliki Papadimitrakopoulou, UT/MD Anderson Cancer Center, United States
George Pavlakis, NCI at Frederick, United States
Spyros Retsas, Cromwell Hospital, United Kingdom
Philippe Rougier, Department of Gastroenterology, Hospital Ambroise Paris, France
Giorgio Scaglioti, University of Torino, San Luigi Hospital, Italy
T.C. Theoharides, Tufts University School of Medicine, Tufts Medical Center, United States
Athanassios Anagnostopoulos, Henry Dunant Hospital, Greece
Gerasimos Aravantinos, "Agioi Anargyroi" Hospital, Greece
Athanassios Athanassiadis, General Hospital of Larissa "Koutlimpaneio & Triantafylleio", Greece
Dimitrios Bafaloukos, Metropolitan Hospital, Greece
Aristotelis Bamias, University General Hospital of Athens "Alexandra", Greece
Ioannis Boukovinas, Theageneio Anticancer Hospital, Greece
Christos Emmanouilides, Interbalkan Medical Center, Greece
Helen Gogas, University General Hospital of Athens "Laiko", Greece
Stylianos Kakolyris, University General Hospital of Alexandroupoli, Greece
Athanasios Karampeazis, 401 General Military Hospital of Athens, Greece
Michael Karamouzis, Medical School, University of Athens, Greece
Ourania Katopodi, Bioclinic of Athens, Greece
Georgios Klouvas, Metropolitan Hospital, Greece
Christos Kosmas, General Anticancer Hospital "Metaxa", Greece
Georgios Koumakis, "Agios Savvas" Anticancer Hospital, Greece
Thomas Makatsoris, University General Hospital of Patra - Rio, Greece
Dimitris Mavroudis, University General Hospital of Heraklion, Greece
Michael Nikolaou, "Ippokrateion" University Hospital of Athens, Greece
Christos Panopoulos, "Agios Savvas" Anticancer Hospital, Greece
Christos Papadimitriou, University General Hospital of Athens "Alexandra", Greece
Christos Papandreou, University General Hospital of Larissa, Greece
Konstantinos Papazissis, Theageneio Anticancer Hospital, Greece
Dimitrios Pectasides, General Hospital of Athens "Ippokratio", Greece
Georgios Pentheroudakis, University General Hospital of Ioannina, Greece
Amanda Psyrri, University General Hospital of Athens "Attikon", Greece
Evangelia Razis, Hygeia Hospital, Greece
Georgios Samonis, University General Hospital of Heraklion, Greece
Ioannis Souglakos, University General Hospital of Heraklion, Greece
Kyriakos Souliotis, Associate Professor, University of Peloponnese, Greece
Kostas Syrigos, "Sotiria" Regional Chest Diseases Hospital of Athens, Greece
Dimitrios Tryfonopoulos, "Agios Savvas" Anticancer Hospital, Greece
Lambros Vamvakas, University General Hospital of Heraklion, Greece
Michael Vaslamatzis, General Hospital of Athens "Evaggelismos", Greece
Spyridon Xynogalos, General Hospital of Athens "Evaggelismos", Greece
Nikolaos Ziras, General Anticancer Hospital "Metaxa", Greece
Koulis Giannoukakos, NSCR Demokritos, Greece
Emmanouil Saloustros, General Hospital of Heraklion "Venizeleio- Pananeio", Greece
Charalambos Andreadis, Theageneio Anticancer Hospital, Greece
Dimitrios Mavroudis, University of Crete, Greece
Evaggelos Briasoulis, University of Ioannina, Greece
Sam Murray, Genekor SA, Greece
Vasiliki Kotoula, University of Thessaloniki, Greece
Petroula Arapantoni-Dadioti, Metropolitan Hospital General Anticancer Hospital "Metaxa", Greece
Savvas Papadopoulos, Hygeia Hospital, Greece
Dimitris Kardamakis, University of Patras, Greece
Despoina Misailidou, Interbalkan Medical Centre, Greece
Odysseas Zoras, Medical School University General Hospital of Heraklion, Greece
Evaggelos Xynos, University Hospital of Herakleion, Greece
De Gruyter Poland
Bogumiła Zuga 32A Str.
01-811 Warsaw, Poland
Forum of Clinical Oncology ist in den folgenden Services indiziert:
- Baidu Scholar
- Cabell's Whitelist
- CNKI Scholar (China National Knowledge Infrastructure)
- CNPIEC - cnpLINKer
- DOAJ (Directory of Open Access Journals)
- Google Scholar
- Japan Science and Technology Agency (JST)
- KESLI-NDSL (Korean National Discovery for Science Leaders)
- Naver Academic
- Naviga (Softweco)
- QOAM (Quality Open Access Market)
- SCImago (SJR)
- Semantic Scholar
- Ulrich's Periodicals Directory/ulrichsweb
- WanFang Data
- WorldCat (OCLC)
All submissions must be made via online submission system Editorial Manager: www.editorialmanager.com/fco
In case of any technical problems, please contact the Journal Office at: email@example.com
Open Access Statement
The journal is an Open Access journal that allows a free unlimited access to all its contents without any restrictions upon publication to all users.
Forum of Clinical Oncology is an open journal, available online on, among others, www.jultrason.pl. It can be accessed free of charge and with no other barriers on the basis of the Creative Commons Attribution-Non Commercial-No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/) – CC-BY-NC-ND (certain rights reserved for the publisher and authors). The license allows for redistribution, presentation and preparation of the material for non-commercial purposes only, as long as it remains in its original form (without creating derivative works). The journal allows the author(s) to hold the copyright and retain publishing rights without restrictions. When deciding to publish an article in “Forum of Clinical Oncology” the author consents to its redistribution on the aforementioned terms and guarantees that the article does not infringe the rights of the third party.
Article Processing Charge (APC)The journal does not have article processing charges (APCs) nor article submission charges.